Price
$529.59+7.14%1Y
1M+9.36%1Y+7.14%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average7/10
Value39
Quality90
Momentum37
Growth47
P/E (TTM)27.8
Market Cap$114.63B
1Y Return+7.14%
5Y Return+153.45%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $5.90B (+89.59%)
●JOURNAVX grew +2130.77% YoY●Collaborativeand Royalty -100.00% YoY
SegmentLatestQoQYoY
- Cystic Fibrosis Products$2.92B-+6.20%
- TRIKAFTAKAFTRIO$2.35B-11.26%-7.13%
- ALYFTREK$424.4M+71.82%+687.38%
- Manufactured Product Other$135.9M-22.70%-12.49%
- CASGEVY$42.9M+153.85%+202.11%
- JOURNAVX$29.0M+47.96%+2130.77%
- CASGEVYAnd JOURNAVX---
- Collaborativeand Royalty$0.00--100.00%
- Kalydeco---
- ORKAMBI---
- Other Cystic Fibrosis Products---
- SYMDEKOSYMKEVI---